A Study to Evaluate the Safety and Efficacy of COVID-19 Convalescent Plasma (CCP) Transfusion to Prevent COVID-19 in Adult Recipients Following Hematopoietic Stem Cell Transplantation

NCT05904067 · clinicaltrials.gov ↗

NA

Phase

UNKNOWN

Status

72

Enrollment

OTHER

Sponsor class

Conditions

COVID-19
Hematopoietic Stem Cell Transplantation

Interventions

BIOLOGICAL: COVID Convalescent Plasma

Sponsor

Institute of Hematology & Blood Diseases Hospital, China